135
Participants
Start Date
June 29, 2012
Primary Completion Date
January 21, 2016
Study Completion Date
January 21, 2016
Bevacizumab
Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Onartuzumab
Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
Placebo
Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
HUG; Oncologie, Geneva
Universitätsspital Zürich; Klinik für Neurologie, Zurich
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin
Hopital de La Timone - CHU de Marseille; Service de neuro-oncologie - Hôpital Adultes - 12ème étage, Marseille
Fondazione IRCCS Ospedale Maggiore Policlinico; Gastroenterologia, Milan
Fondazione IRCCS Istituto Neurologico C. Besta; Neuro-oncologia Sperimentale e Terapia Genica, Milan
Universitatsklinikum Hamburg-Eppendorf; Klinik und Poliklinik fur Neurochirurgie, Hamburg
University of Virgina, Charlottesville
Virginia Cancer Institute, Richmond
Spedali Civili di Brescia, Brescia
Pius-Hospital, Oldenburg
Duke University Medical Center, Durham
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Málaga
Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona
Hopital Purpan, Toulouse
Moffitt Cancer Center, Tampa
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building), St. Petersburg
Florida Cancer Specialists - Englewood, Englewood
Centre Val Aurelle Paul Lamarque; Medecine B3, Montpellier
University of Alabama At Birmingham; Neuro-Oncology, Birmingham
Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville
Ospedale Bellaria; U.O. Oncologia Medica, Bologna
A.O. Universitaria Di Parma; Oncologia Medica, Parma
Ico Rene Gauducheau; Oncologie, Saint-Herblain
Hatton Research Institutes, Cincinnati
Presidio Ospedaliero Marconi Bufalini; U.O. di Oncologia, Cesena
Henry Ford Health System, Detroit
Ärztehaus Velen, Ibbenbühren
Universitätsklinikum Köln, Cologne
Universitätsklinikum Bonn; Medizinische Klinik und Poliklinik I; Allgemeine Innere Medizin, Bonn
Hôpital Central; Departement de Neuro-Oncologie, Nancy
Klinikum der Johannes Gutenberg Uni Mainz; Studienz. Neurologie, Klinik und Poliklinik Neurologie, Mainz
Az. Osp. Pisana Ospedale S. Chiara; U.O. Di Reumatologia, Pisa
Hopital Roger Salengro, Lille
Northshore University Health System; Cardiology, Evanston
Klinikum Joh.Wolfg.Goethe-UNI Senckenbergisches Institut für Neuroonkologie, Frankfurt am Main
North Western Univ; Neurology, Chicago
Hopital neurologique Pierre Wertheimer - CHU Lyon; Neurologie, Bron
Baylor Research Inst., Dallas
Hopital Pitié Salpétrière - CHU; Service de neurologie 2 - Mazarin, Paris
University of Colorado, Aurora
Uni Klinikum München - Großhardern; Med. Klinik U. Poliklinik III - Abt. Onkologie u. Hämatologie, München
Cedars Sinai Medical Center; Neurosurgery, Los Angeles
UCLA, Los Angeles
Hopital Avicenne; Neurologie, Bobigny
USCF - Neurosurgery, San Francisco
Stanford Comprehensive Cancer Center, Stanford
Seattle Cancer Care Alliance; Investigational Drug Service, Seattle
Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton
London Health Sciences Centre, London
Sunnybrook Health Science Centre, Toronto
Princess Margaret Hospital; Pencer Brain Tumour Centre, 18-727, Toronto
McGill University; Montreal Neurological Institute; Oncology, Montreal
CHUS Hopital Fleurimont; CRC, Sherbrooke
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona
Hospital Clinic i Provincial; Servicio de Farmacia, Barcelona
Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona
Bristol Haematology and Oncology Centre, Bristol
Sarah Cannon Research Institute, London
Nottingham City Hospital; David Evans Centre, Nottingham
Hoffmann-La Roche
INDUSTRY